The expansion will allow AGC Biologics to generate around 250-300 new workplaces in Denmark. The production will be based on genetically modified organisms, biosafety level 1, manufactured with single-use technology in clean rooms.
The new facility will include a manufacturing building, an office building and a visitors center. The manufacturing building will consist of four levels totalling approximately 8,000 square meters: distributed across manufacturing, quality control laboratories, technical and warehouse areas.
The site will more than double AGC Biologics’ single-use bioreactor mammalian cell-culture capacity in Copenhagen: with the company noting the biopharmaceuticals CDMO market continues to grow double digits annually.
“This expansion, in addition to the biologics facilities in Seattle WA, Boulder CO, and Chiba Japan, represents the commitment and the dedication that AGC Biologics has in providing high-level technological solutions to its current and future customers,” says the company.
Seattle-headquartered AGC Biologics provides development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), viral vectors and genetically engineered cells.
The company’s global network spans the US, Europe and Asia: with cGMP-compliant facilities in Seattle, Washington; Boulder, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan.